A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
NCT02411136
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
AMG 623
DRUG:
Placebo
Sponsor
Amgen